Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Old Port Advisors

Old Port Advisors decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 4.6% during the 4th quarter, Holdings Channel reports. The fund owned 12,576 shares of the company’s stock after selling 610 shares during the quarter. Old Port Advisors’ holdings in Moderna were worth $523,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna during the 2nd quarter worth about $26,000. Plato Investment Management Ltd boosted its holdings in Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after purchasing an additional 288 shares in the last quarter. Larson Financial Group LLC increased its stake in Moderna by 1,753.1% in the second quarter. Larson Financial Group LLC now owns 593 shares of the company’s stock valued at $70,000 after purchasing an additional 561 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in Moderna in the second quarter valued at approximately $75,000. Finally, Rothschild Investment LLC acquired a new stake in Moderna during the second quarter worth approximately $78,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on MRNA shares. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a report on Monday, November 18th. TD Cowen dropped their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. JPMorgan Chase & Co. reduced their target price on Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday, November 26th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $79.50.

Moderna Price Performance

Moderna stock traded up $1.55 during mid-day trading on Thursday, hitting $43.13. 1,843,017 shares of the company were exchanged, compared to its average volume of 5,139,064. The business’s 50 day simple moving average is $44.06 and its two-hundred day simple moving average is $73.87. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47. The company has a market capitalization of $16.60 billion, a P/E ratio of -7.41 and a beta of 1.58. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.39) earnings per share. Analysts forecast that Moderna, Inc. will post -9.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 3,379 shares of company stock worth $158,195. Insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.